Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V175 and V175A in Healthy Adults

NCT07855510 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT07855510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07855510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V175 and V175A in Healthy Adults
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 27, 2026
Completion date
August 8, 2028
Enrollment
564 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lower respiratory tract infection